相关实验视频

Updated: Apr 11, 2026

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt

Published on: May 7, 2015

对比不同评分模型的有效性,以预测肝脏脑病变后的TIPS在肝硬化患者的疗效

Xin-Jian Xu¹, Liang Yin², Yi-Jiang Zhu²

¹Department of Interventional Radiology, Jiangyin Hospital Affiliated to Nantong University, Jiangyin, China.

Annals of medicine

|June 6, 2025

概括

弗赖堡的TIPS后生存指数 (FIPS) 和CLIF-Consortium急性减补 (CLIFC-AD) 评分有效预测了肝硬化症 (HE) 在肝硬化患者,特别是那些患有肉类的人中,经过状肝脏内移植系统 (TIPS) 后的严重肝硬化症.

科学领域:

肝病学肝病学是一种肝病学.
胃肠病学胃肠病学
临床预测模型临床预测模型

背景情况:

肝脏脑病变 (HE) 是一种严重的并发症,发生在肝硬化患者的经内肝脏内移植系统分流 (TIPS) 放置后.
准确预测HE风险对于患者管理和结果至关重要.
现有的评分系统需要对其在预测TIPS后的有效性进行评估.

研究的目的:

为了比较 Child-Pugh,末期肝病 (MELD) 模型,CLIF-Consortium急性减补 (CLIFC-AD) 和弗赖堡TIPS后生存指数 (FIPS) 预测性表现,对明显和严重的HE.
评估这些分数在TIPS之后的不同时间点预测高等教育发展的有用性.

主要方法:

在2017年1月至2021年1月期间接受TIPS的406名肝硬化患者的回顾性分析.
基于差异化 (C指数),校准,临床实用性和TIPS后1,3,6和12个月的整体表现的评分模型的评估.
针对sarcopenic患者的具体分析,以确定这个子组的得分表现.

主要成果:

在所有评估的模型中,公开的HE的预测性能通常很低.
在TIPS后的1个月和12个月,FIPS显示出对严重的HE的优异预测能力 (C指数:0.781,0.705).
FIPS和CLIFC-AD显示出在肉患者中严重的HE的良好预测能力 (FIPS:C指数0.863,0.757;CLIFC-AD:C指数0.748,0.732). 在FIPS中,严重的HE (HR = 3.520) 的危险比率最高,而公开的HE (HR = 2.132) 的危险比率在CLIFC-AD中最高.

结论:

FIPS和CLIFC-AD分数是预测TIPS后严重的HE的有价值工具.
这些评分在鉴定 sarcopenic 肝硬化患者中严重的HE 风险方面具有特别的实用性.
进一步的研究可能会完善FIPS和CLIFC-AD在临床实践中的使用,用于TIPS后的HE风险分层.

关键词:

在CLIFC-AD中获得分数.查尔德-普格评分 (Child-Pugh score) 是一个指标.在FIPS中,分数是FIPS分数.在MELD中,得分是MELD.提示提示 (TIPS) 是一个提醒.肝脏脑病变 - 肝脏脑病变 - 肝脏脑病变

更多相关视频

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Published on: August 1, 2018

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...